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Abstract
Purpose Although corticosteroids are frequently used in patients with advanced cancer, few studies have examined the impact of
these drugs on patient-reported sleep. We aimed to examine the short-term impact of methylprednisolone on patient-reported
sleep in patients with advanced cancer.
Methods Patient-reported sleep was a predefined secondary outcome in a prospective, randomized, placebo-controlled, double-
blind trial that evaluated the analgesic efficacy of corticosteroids in advanced cancer patients (18+), using opioids, and having
pain ≥ 4 past 24 h (NRS 0–10). Patients were randomized to the methylprednisolone group with methylprednisolone 16 mg × 2/
day or placebo for 7 days. The EORTC QLQ-C30 (0–100) and the Pittsburgh Sleep Quality Index questionnaire (PSQI) (0–21)
were used to assess the impact of corticosteroids on sleep at baseline and at day 7.
Results Fifty patients were randomized of which 25 were analyzed in the intervention group and 22 in the control group. Mean
age was 64 years, mean Karnofsky performance status was 67 (SD 13.3), 51% were female, and the mean oral daily morphine
equivalent dose was 223 mg (SD 222.77). Mean QLQ-C30 sleep score at baseline was 29.0 (SD 36.7) in the methylprednisolone
group and 24.2 (SD 27.6) in the placebo group. At day 7, there was no difference between the groups on QLQ-C30 sleep score
(methylprednisolone 20.3 (SD 32.9); placebo 28.8 (SD 33.0), p = 0.173). PSQI showed similar results.
Conclusions Methylprednisolone 16 mg twice daily for 7 days had no impact on patient-reported sleep in this cohort of patients
with advanced cancer.
Trial registration Clinical trial information NCT00676936 (13.05.2008)
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Background
Patients with advanced cancer often report poor sleep quality
with a prevalence that varies from 40 to 96% across studies
[1–6]. The cancer disease and the cancer treatments are factors
that probably contribute to sleep disturbances [7]. Treatment
with corticosteroids may be a precipitating factor involved in
the development of insomnia in patients with cancer [8–11].
Corticosteroids are associated with a variety of adverse effects
in which sleep disturbance is one of the short-term effects
[12–15]. These drugs are frequently administered to patients
with advanced cancer [16–21], but usage varies between
countries. For instance, a cross-sectional study of European
cancer patients using opioids showed that 34% in Germany,
49% in Norway, and 72% of patients in Italy were using
corticosteroids [22]. The indications for corticosteroid use in
patients with advanced cancer are wide, including alleviation
of distressing symptoms such as pain, anorexia, fatigue, and
dyspnea as well as improving quality of life and sense of well-
being [16, 17, 20, 21]. Some patients also use corticosteroids
as a part of anti-cancer therapy or for other medical conditions.
Few studies have examined the impact of corticosteroids
on patient-reported sleep in patients with advanced cancer.
Mercadante et al. demonstrated an inverse relation between
the use of corticosteroids and sleep assessed by the Athens
Insomnia Scale in patients with advanced cancer [23].
However, due to the cross-sectional design, causality between
corticosteroids and sleep quality could not be assessed.
Second, in a prospective survey on the use of dexamethasone
in in and outpatients with advanced malignant disease, Hardy
et al. demonstrated that mild sleep disturbance was reported
by 17% of the patients after start of corticosteroid treatment
[24]. In another study, Hatano et al. demonstrated that 19% of
patients with advanced cancer experienced sleep disturbance
1 week after start of dexamethasone given for anorexia [25].
In the latter study, sleep was rated by healthcare workers ac-
cording to the National Cancer Institute’s Common Toxicity
Criteria for Adverse Events Likert scales. However, as sleep
disturbance was not assessed by patient-reported outcome
measures, it is likely underestimated. Furthermore, none of
these studies used standardized doses of corticosteroids nor
did they include a control group. Finally, Yennurajalingam
et al. performed a randomized, double-blind, placebo-
controlled study on the use of dexamethasone 4 mg orally
twice daily for 14 days for cancer-related fatigue in patients
with advanced cancer. They found no difference in sleep using
a numeric scale (NRS), (0, no symptoms; 10, worst possible
severity) between dexamethasone and placebo at day 15 [26].
To summarize, few studies have examined the impact of stan-
dardized doses of corticosteroids on sleep by a longitudinal ran-
domized controlled design in patients with advanced cancer.
Given the high prevalence of both sleep disturbances and corti-
costeroid use in patients with advanced cancer, it is essential to
know whether corticosteroids aggravate sleep in these patients.
The aim of this study was to investigate patient-reported sleep, a
predefined secondary outcome in the randomized
Corticosteroids for Cancer Pain Trial (NCT00676936) [27].
Methods
Overall design and participants
The randomized Corticosteroid for Cancer Pain Trial [27] in-
vestigated the analgesic effect of methylprednisolone on pain,
with patient-reported sleep as a predefined secondary outcome
in a prospective, randomized, placebo-controlled, double-
blind design [27]. Eligible patients in the randomized con-
trolled trial had verified malignant disease, aged 18 years or
above, self-reported average pain ≥ 4 last 24 h (assessed on a
Numerical Rating Scale (NRS) 0–10), used opioids for mod-
erate or severe cancer pain, and had an expected length of
survival of more than 4 weeks. Exclusion criteria were severe
pain, defined as 8 or above on the NRS last 24 h; regular
corticosteroid use; initiated radiotherapy or systematic cancer
treatment in the past 4 weeks; diagnosed with diabetes
mellitus, peptic ulcer disease, spinal cord compression, or be-
ing in need of bone surgery; and ongoing treatment with non-
steroidal anti-inflammatory drugs. Patients with obvious cog-
nitive impairment as judged by the treating physician accord-
ing to standard criteria (e.g., confusion, disorientation, low
attention span and incoherent speech) were also not eligible
[27]. Five palliative care and outpatient oncology services in
Norway participated in the study [27].
Study treatment
Patients were randomized to methylprednisolone 16 mg or
placebo twice daily for 7 days. The study drug was adminis-
tered in the morning and before 6 p.m. in the afternoon.
Patients and members of the research team were all blinded
to treatment assignment throughout the study. Details of the
study procedures are described in the original article [27].
Outcome measures
Sleep
Sleep, a secondary outcome predefined in the protocol [27],
was assessed at baseline and day 7 using the European
Organization for Research and Treatment of Cancer Quality
of Life Questionnaire Core 30 (QLQ-C30) [28]. The QLQ-
C30 includes a single question assessing sleep difficulty:
“(During the past week) Have you had trouble sleeping?”
The QLQ-C30 sleep item has four response categories from
“not at all” to “very much”. The raw scores are transformed
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linearly to a scale from 0 to 100, i.e., QLQ-C30 sleep score,
where a high score represents more sleeping trouble [28]. A
mean difference of 10–20 points is described as a moderate
change that is perceptible to patients [29]. Thus, a difference
of 15 points on the QLQ-C30 sleep score was considered
clinically significant in this trial.
Sleep quality was also assessed by the Pittsburgh Sleep
Quality Index questionnaire (PSQI) [30]. The PSQI is a 19-
item self-report questionnaire that assesses sleep quality. The
recall period is 1 month. The questionnaire comprises seven
domains: subjective sleep quality, sleep latency, sleep dura-
tion, normal sleep efficiency, sleep disturbances, the applica-
tion of sleep medicine, and daytime dysfunction [30]. Each
domain has a response score ranging from 0 to 3, with lower
scores indicating better sleep quality. The seven component
scores are summed to yield a PSQI total global score (0–21).
PSQI total global scores ˃ 5 indicate poor sleep [4, 30].
Cognitive function was assessed pre- and posttreatment by
the Mini Mental State Exam (MMSE). The MMSE has 20
items and a sum score of 30 points [31]. Performance status
was rated by the Karnofsky performance status (KPS) [32].
Patients reported their daily analgesic consumption, and opi-
oid dosages were converted to oral morphine equivalents [33].
Statistical analysis
Power calculations were presented in the original article and
were based on the primary outcome of average pain intensity
measured at day 7 (on an NRS 0–10 (0 = no pain, 10 = worst
imaginable pain) [27]. The estimated sample size was 22
evaluable patients in each group.
Demographic variables are reported as means with stan-
dard deviation (SD) or frequencies. The main sleep outcome
was the QLQ-C30 sleep score day 7 after treatment.
Difference between the intervention group and the control
group in QLQ-C30 sleep score on day 7 was assessed using
a general linear model (ANCOVA) including baseline values
as a covariate in the model. We also calculated the change
score for each patient by subtracting the baseline sleep score
(day 0) from the score at end of treatment (day 7).
Differences between the two groups were also assessed in
explorative analyses using the global PSQI score and each of
the PSQI dimensions as the dependent variable in the
ANCOVA model, i.e., subjective sleep quality, sleep latency,
sleep duration, sleep efficiency, sleep disturbances, sleepmed-
ication, and dysfunction (0–3), and the patient-reported sleep
onset latency in minutes. The baseline value was in each case
used as a covariate in the model.
There was one missing item in the PSQI-sleep disturbance
scale in the PSQI. This was imputed by the last observation
carried forward. One patient had a missing value in the QLQ-
C30 sleep item at baseline, and one patient had a missing
value at day 7; no imputation method was used, as these were
single items.
A two-sided P value of ˂ 0.05 was considered statistically
significant. P values were not adjusted for multiple testing.
SPSS statistical software (version 25.0) was used.
Results
Study population
Fifty patients were randomized to methylprednisolone 16 mg
twice daily or placebo, 26 were allocated to the methylpred-
nisolone group and 24 to the placebo group, of which 25 could
be evaluated in the methylprednisolone group and 22 in the
placebo group (Fig. 1). Figure 1 reports the essentials for
analysis of sleep and is adapted from the diagram in the orig-
inal trial [27].
The overall mean age of patients was 64.1 years (SD 10.1),
mean Karnofsky performance status was 67.1 (SD 13.3), 51%
were female, and the mean opioid dose was 223 mg (SD 223).
Table 1 shows baseline demographics and clinical character-
istics for each treatment group.
Patient-reported sleep
The mean QLQ-C30 sleep score at baseline was 29.0 (SD
36.7) in the methylprednisolone group (n = 23) and 24.2 (SD
27.6) in the placebo group (n = 22). At day 7, after controlling
for pre-intervention scores on sleep, there were neither any
clinical nor any statistically significant differences in the
QLQ-C30 sleep score with methylprednisolone compared
with placebo (ANCOVA, F = 1.92, p = 0.173) (Table 2;
Fig. 2). The mean change in the QLQ-C30 sleep score was
− 8.7 (SD 25.1) in the methylprednisolone group and 4.6 (SD
34.6) in the placebo group.
At baseline, themean PSQI global score was 8.2 (SD 4.3) and
7.6 (SD 3.7) in the methylprednisolone (n = 25) and placebo
(n = 22) groups, respectively. At baseline, 18 of 25 (72%) of
the patients in the methylprednisolone group and 15 of 22
(68%) in the placebo group were categorized as poor sleepers
(PSQI global score > 5). At day 7, there were no significant
differences between the groups in the global PSQI score (p=
0.809) or any of the single PSQI dimensions (Table 2).
Discussion
The main finding of this trial was that treatment with methyl-
prednisolone 16 mg twice daily for 7 days in patients with
advanced cancer did not result in more patient-reported sleep
problems as measured by the QLQ-C30 sleep score and the
PSQI.
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Table 1 Demographic and clinical characteristics at inclusion
Characteristics Methylprednisolone (n = 25) Placebo (n = 22)
Age (years), mean (SD) 62.5 (8.6) 66.0 (11.3)
Gender, n (%)
Female 13 (52) 11 (50)
Male 12 (48) 11 (50)
Body mass index (kg/m2), mean (SD) 24.2 (5.8) 21.7 (3.4)
Cancer diagnosis, n (%)
Breast 1 (4) 1 (5)
Prostate 2 (8) 3 (14)
Gastrointestinal 6 (24) 5 (23)
Lung 6 (24) 5 (23)
Gynecologic 5 (20) 5 (23)
Other 7 (28) 3 (14)
Cognitive function, (MMSE), mean 27.1 27.0
Performance score, (KPS), mean (SD) 66.6 (14.1) 65.6 (13.8)
Concomitant disease, n (%)
Cardiac 4 (16) 4 (18)
Vascular 5 (19) 8 (36)
Lung 3 (12) 4 (18)
Opioid analgesics, mean (SD) oral morphine equivalentsa 273.8 (256.8) 165.8 (163.9)
Mean number of other medications (SD) 4.0 (2.1) 4.5 (2.0)
Hypnoticsb, n (%) 9 (35) 6 (25)
Antidepressantsc, n (%) 4 (15) 4 (18)
Benzodiazepinesd, n (%) 3 (12) 6 (25)
SD standard deviation, MMSEMini-Mental State Examination [31], KPS Karnofsky Performance Score: 0 (dead) to 100 (normal activity) [32]
amg per day
bHypnotics, i.e., zopiclone, nitrazepam, alimemazine
c Antidepressants (citalopram, escitalopram, sertraline, mirtazapine)
d Benzodiazepines (oxazepam)
Assessed for eligibility (n = 592) 
Not eligible (n = 542) 
 Not meeting inclusion criteria (n = 60) 
 Declined to participate (n = 13) 
 Exclusion criteria (n = 462) 
  Other reasons (n = 7) 
Analysed, secondary outcome (n = 25)  
 Excluded from analysis (n=0)  
Lost to follow-up (n = 0) 
Discontinued methylprednisolone (n = 1)  
 
Allocated to methylprednisolone (n = 26) 
 Received allocated intervention (n = 26) 
 
Lost to follow-up (n = 0) 
Discontinued placebo (n = 1)  
 
Allocated to placebo (n = 24) 
 Received placebo (n= 23) 
 Did not receive allocated intervention (n= 1)   
Analysed, secondary outcome (n = 22) 
 Excluded from analysis (n= 0) 
Randomized (n = 50) 
Fig. 1 CONSORT flow diagram
of the progress through the phases
of the trial. The figure reports the
essentials for analysis of sleep and
is adapted from the diagram in the
original trial [27]
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Our finding is similar to the results of a prospective, ran-
domized, double-blind, placebo-controlled trial which primar-
ily assessed the effects of oral dexamethasone 4 mg twice
daily on cancer-related fatigue [26]. In that study,
Yennurajalingam et al. found no change in sleep scores, as
measured by a NRS of 0 to 10, in the dexamethasone group
compared with the placebo group during 14 days of treatment
in patients with advanced cancer. Our findings also agree with
a cross-sectional study that observed no association between
sleep disturbance and the use of corticosteroids in 442 ad-
vanced cancer patients in outpatient palliative care [34].
In contrast, other studies have demonstrated an asso-
ciation between use of corticosteroids and sleep distur-
bance in patients with advanced cancer. Mercadante
et al. reported that use of corticosteroids was positively
associated with subjective sleep disturbance [23] and
was associated with significant sleep problems [19].
Moreover, insomnia was frequently reported in two pro-
spective studies on corticosteroids for symptom control
in palliative patients [24, 25]. However, these studies
are limited by lack of a comparison group and not using
a standardized dose of corticosteroids.
Table 2 Sleep scores at baseline and Day 7
Variable Baseline Mean (SD) Day 7
Mean (SD)
Mean change
D0 to D7 (SD)
p valuea
QLQ-C30 Sleep scoreb
Methylprednisolone 29.0 (36.7) 20.3 (32.9) − 8.7 (25.1) 0.173
Placebo 24.2 (27.6) 28.8 (33.0) 4.6 (34.6)
PSQI, global scorec
Methylprednisolone 8.24 (4.25) 8.52 (5.02) 0.28 (2.01) 0.809
Placebo 7.64 (3.67) 8.05 (3.66) 0.41 (1.68)
Subjective sleep qualityd
Methylprednisolone 1.08 (0.86) 0.92 (0.86) − 0.16 (0.62) 0.305
Placebo 0.95 (0.79) 1.0 (0.82) 0.05 (0.58)
Sleep latencyd
Methylprednisolone 1.20 (1.04) 1.24 (1.05) 0.04 (0.79) 0.217
Placebo 0.95 (0.90) 1.32 (0.84) 0.37 (0.66)
Sleep durationd
Methylprednisolone 0.48 (0.87) 0.60 (1.00) 0.12 (0.73) 0.994
Placebo 0.32 (0.78) 0.45 (0.85) 0.13 (0.35)
Habitual sleep efficiencyd
Methylprednisolone 1.04 (1.10) 1.28 (1.21) 0.24 (0.78) 0.704
Placebo 0.82 (1.05) 1.00 (1.20) 0.18 (0.66)
Sleep disturbanced
Methylprednisolone 1.32 (0.63) 1.32 (0.48) 0.00 (0.71) 0.805
Placebo 1.36 (0.58) 1.36 (0.49) 0.00 (0.66)
Use of sleep medicationd
Methylprednisolone 1.80 (1.44) 1.84 (1.46) 0.04 (0.20) 0.171
Placebo 1.73 (1.45) 1.68 (1.49) − 0.05 (0.21)
Daytime dysfunctiond
Methylprednisolone 1.32 (1.03) 1.32 (0.94) 0.00 (1.00) 0.414
Placebo 1.50 (0.96) 1.23 (0.87) − 0.27 (0.90)
Sleep onset latency, mine
Methylprednisolone 23.7 (18.8) 22.5 (17.6) − 1.1 (13.6) 0.118
Placebo 30.3 (39.1) 32.6 (36.4) 3.5 (11.6)
a p value for comparison of follow up scores for the study groups (methylprednisolone and placebo) from the ANCOVA model
b EORTC QLQ-C30 symptom scale (0–100) where a high score denotes higher symptom burden [28]
c Pittsburg Sleep Quality Index global score 0–21, where a high score denotes more sleep problems [30]
d PSQI component score 0–3
e Sleep onset latency in minutes from the PSQI
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Several issues need to be addressed to interpret the findings
from studies of sleep in palliative care. First, it may be difficult
to differentiate corticosteroid adverse effects from symptoms
related to a progressing malignant disease in patients with
advanced cancer [24]. Compared to patients with less ad-
vanced disease, an isolated effect of corticosteroid use on
sleep may be difficult to ascertain in patients with advanced
disease who often have a higher symptom burden [35]. For
instance, Chrousos et al. performed a placebo-controlled ran-
domized trial and found that 50% of patients taking prednis-
olone for optic neuritis reported sleep disturbance, compared
with 20% in the placebo group [36]. Additionally, corticoste-
roids may improve other symptoms in patients with advanced
cancer which may indirectly influence sleep. In the present
study, patient-reported appetite, fatigue, and patient satisfac-
tion significantly improved in the methylprednisolone group
[27]. Another example is a randomized controlled trial show-
ing corticosteroids to be effective in improving cancer-related
fatigue [26]. A qualitative study by Lundström et al. reported
that corticosteroids administered for symptom control in pa-
tients with advanced metastatic cancer had positive existential
consequences [37]. Moreover, studies have shown an associ-
ation between the symptoms of sleep and fatigue [38, 39].
Thus, in patients with advanced cancer positive effects of
corticosteroids on other symptoms that influence sleep may
counter-balance potential direct negative short-term effects
from corticosteroids on patient-reported sleep.
The second issue relates to the level of patient-reported
sleep at baseline. In our trial, the QLQ-C30 sleep scores of
24 and 29 (0–100) in the study groups at baseline are in line
with results from other studies in advanced-cancer patients
[40–42], indicating poorer sleep compared with the general
population [43]. Moreover, we found that 70% of the patients
reported poor sleep quality on the PSQI before study start,
echoing results from other studies with prevalence of poor
sleep quality from 40 to 96% in patients with advanced cancer
[2–5]. Thus, poor sleep quality at baseline in our trial might
explain why these patients responded differently to corticoste-
roids than observed in other cohorts.
The third issue relates to the dose and timing of corticoste-
roids. The equipotent dose of methylprednisolone 32 mg in
our trial equals about 6.4 mg dexamethasone, which was
slightly lower than the dexamethasone dose of 8 mg in the
randomized controlled trial by Yennurajalingam et al. [26].
The daily dose of corticosteroids is a risk factor for the devel-
opment of sleep disturbance [15], i.e., higher doses of corti-
costeroids having more impact on sleep quality. Furthermore,
the time of administration of corticosteroids may be an impor-
tant factor for the impact on sleep. In our trial, patients were
requested to take methylprednisolone in the morning and be-
fore 6 p.m. in the afternoon. Additionally, methylprednisolone
has a shorter half-life compared with dexamethasone. This
may have prevented sleep disturbance attributed to adminis-
tration of corticosteroids late in the evening.
A final issue is the duration of the present trial. Since patients
with advanced cancer are frail, attrition may make a longer study
duration unfeasible [44]. On the other hand, a short studywill not
detect long-term effects. However, a review reported that 39–
86% of adverse psychiatric effects, including insomnia, occurred
during the first week after start of corticosteroids [15]. Thus, we
consider a duration of 7 days to be adequate to explore the short-
term impact of corticosteroids on patient-reported sleep in this
cohort of patients with advanced cancer.
We recognize some limitations in this trial. First, patient-
reported sleep was a secondary outcome in this randomized
trial. Accordingly, the initial sample size estimation and pow-
er calculations were estimated for changes in self-reported
pain, not sleep. Further, the sample size was small, which is
Fig. 2 Mean score of QLQ-C30
sleep item according to treatment
arm. A higher score represents
more sleeping trouble. There were
no statistically significant
difference in change of sleep
problems between the treatment
arms (error bars 95% CI)
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reflected by the wide 95% confidence intervals. However, the
mean QLQ-C30 sleep score actually improved in the methyl-
prednisolone group compared with a deterioration in the pla-
cebo group, which supports the conclusion that a deterioration
due to a corticosteroid induced adverse effect in this cohort is
unlikely (i.e., a type II error). Second, the recall period of
PSQI of 1 month makes it less appropriate for studies with
shorter intervention periods. However, in the present trial, we
could not detect an impact on sleep after 7 days of intervention
neither with a questionnaire using a recall period of 1 week
(QLQ-C30) nor with a recall period of 1 month (PSQI).
Moreover, a study that examined the ecological validity for
each of the items on the PSQI reported that patients’ results
were comparable regardless of the length of the recall period
from 3 days through a month [45]. Third, only a minor part of
screened patients was eligible which leads to a risk for a se-
lection bias. Finally, despite randomization, the corticosteroid
group had slightly higher absolute levels of opioid consump-
tion at baseline compared with the placebo group. Exploratory
analysis including opioid consumption as a covariate did not
change the results (data not reported). Thus, it is highly un-
likely that the opioid consumption had any influence on the
results.
This trial has several strengths. First, this was a random-
ized, placebo-controlled, double-blind trial using a standard-
ized dosing of corticosteroids. Second, this trial recruited the
predefined number of patients and had few dropouts com-
pared with other trials in this patient group [26]. Third, the
patient-reported outcomes are consistent with the previously
published investigator report of adverse effects (AEs) in the
present trial. The presence of adverse effects was assessed by
the investigator through semi-structured interviews (presence
of predefined AE category [yes vs. no] at day 7).
“Sleeplessness” was noted by four participants in the methyl-
prednisolone group as compared with three participants in the
placebo group [27]. Finally, we consider these results impor-
tant and relevant for clinical practice. The cohort studied rep-
resented patients with advanced cancer and a high symptom
burden. As corticosteroids are commonly used, it is important
to know that the use of methylprednisolone is well tolerated,
also in terms of sleep.
Conclusions
In conclusion, methylprednisolone 16 mg twice daily for
7 days had no impact on patient-reported sleep in a cohort of
patients with advanced cancer treated with opioids. The ma-
jority of patients in this cohort reported poor sleep quality at
baseline, emphasizing the need to address and treat sleep dis-
turbances. The effects of long-term administration of cortico-
steroids on sleep in patients with advanced cancer need to be
examined in a future study.
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